Among the top stories in hematology/oncology this past week were the FDA approval of Vitrakvi for solid tumors with neurotrophic receptor tyrosine kinase gene fusion and trial results indicating that the ketogenic diet is superior to the diet recommended by the American Cancer Society for women with ovarian and endometrial cancers.
Other popular stories included the American Society of Hematology’s comprehensive guidelines to improve the management of venous thromboembolism, study results that suggested that the addition of an altitude sickness drug to chemotherapy may improve management of certain glioblastomas and data indicating that certain breast cancer survivors may be at risk for cognitive decline.
FDA approves Vitrakvi for solid tumors with neurotrophic receptor tyrosine kinase gene fusion
The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation. Read more.
Ketogenic diet superior to standard for women with ovarian, endometrial cancers
The ketogenic diet yielded greater reductions in fat mass and serum insulin levels than the diet recommended by the American Cancer Society among women with ovarian and endometrial cancers, according to results of a randomized, controlled trial. Read more.
A merican Society of Hematology ’s comprehensive guidelines aim to improve management of venous thromboembolism
American Society of Hematology, or ASH, in collaboration with the McMaster University GRADE Centre, published the first six chapters of the ASH Clinical Practice Guidelines on Venous Thromboembolism to improve the diagnosis, treatment and management of blood clots, the society announced in a press event. Read more.
Addition of altitude sickness drug to chemotherapy shows potential in certain glioblastomas
The combination of a common altitude sickness drug to chemotherapy may benefit patients with certain patients with certain types of glioblastoma, according to study results published in Science Translational Medicine. Read more.
Certain breast cancer survivors may be at risk for cognitive decline
Older breast cancer survivors who have certain aging-related phenotypes and genotypes may be at increased risk for cognitive decline, especially after treatment with chemotherapy, according to study results. Read more.